Clinical Trials
22 trialsNCT05735184 2026-03-13
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Kura Oncology, Inc.
Phase 1 Recruiting
NCT07297160 2026-03-04
CALySSEY
Baylor College of Medicine
Phase 1 Not yet recruiting
NCT04593277 2026-01-23
Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA Study
Fred Hutchinson Cancer Center
Phase NA Completed
NCT06988475 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT03162536 2025-09-08
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1/2 Active not recruiting
NCT06582849 2025-08-26
EARN
Washington University School of Medicine
Phase NA Completed
NCT02988466 2025-05-28
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT04537715 2025-02-19
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
Phase 1 Completed
NCT01638533 2025-02-07
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
NCT04190433 2023-05-24
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
Mayo Clinic
Phase 2 Withdrawn
NCT01345019 2022-11-08
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Amgen
Phase 3 Completed
NCT01474681 2020-12-30
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Novartis
Phase 1/2 Completed
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT01222780 2020-01-18
To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Acrotech Biopharma Inc.
Phase 1 Completed
NCT01287104 2019-08-22
A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02118311 2017-12-02
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT02259348 2017-05-30
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00049504 2017-05-17
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01831726 2017-03-20
SIGNATURE
Novartis
Phase 2 Completed
NCT01621477 2017-02-20
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT01616537 2015-11-16
QASICC-EVA
Centre Antoine Lacassagne
Phase NA Terminated
NCT00514722 2013-08-14
Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies
University of California, San Francisco
Phase NA Terminated